Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway, which promotes YAP and TAZ activation resulting in uncontrolled proliferation and impaired differentiation, by inhibiting the transcription
function of TEAD-YAP.
/PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,.
Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecule drugs for.